Pharmaceutical Ming Junuo (Hong Kong Stock Exchange Code: 2126) is an independent and innovative biotechnology company that focuses on developing, producing and commercializing cellular immunotherapy products, and is committed to leading innovation to become a leader in cellular immunotherapy. Established in 2016, Pharmaceutical MingJunuo has successfully built the world's leading comprehensive product development platform for cellular immunotherapy, as well as a cellular immunotherapy product pipeline covering hematologic tumors, solid tumors, and autoimmune diseases. Pharmaceutical Ming Junuo is committed to bringing hope for healing to patients in China and the world with breakthrough, high-quality cellular immunotherapy products, and leading the development of health standards in China's cellular immunotherapy industry.